Altimmune, Inc.

  • Earnings Score
  • Moat Score
  • Market Cap $673.45M
  • PE -7
  • Debt $NaN
  • Cash $31.52M
  • EV $NaN
  • FCF $NaN

Earnings

loading chart...

Sales & Net Margins

loading chart...
Earnings-$103.52M
EBIT-$109.95M
ROE-78%
ROA-74%
Equity$133.38M
Growth Stability-92%
PE-6.51
PB5.05
P/S12.95K
Price/Cash0.05
Net Margins-479K%
Op. Margins-211K%
Earnings CAGR0%
Sales Growth YoY-99%
Sales Growth QoQ0%
Sales CAGR-22%
FCF CAGR0%
Equity CAGR32%
Earnings Stability0
Earnings Growth YoY11%
Earnings Growth QoQ-7%
Sales CAGR 5Y-43%
Equity CAGR 5Y14%
Earnings CAGR 3Y-66%
Sales CAGR 3Y-66%
Equity CAGR 3Y-10%
Market Cap$673.45M
Revenue$52.00K
Assets$147.86M
Cash$31.52M
Shares Outstanding70.93M
Earnings Score6%
Moat Score0%
Working Capital137.12M
Current Ratio16.87
Shares Growth 3y23%
Equity Growth QoQ-13%
Equity Growth YoY-11%

Assets & ROA

loading chart...

Stockholders Equity & ROE

loading chart...
Altimmune Inc is a clinical-stage biopharmaceutical company focused on the development of novel peptide-based therapeutics for the treatment of obesity and liver diseases. The company's lead product candidate, pemvidutide, is a GLP-1/glucagon dual receptor agonist that is being developed for the treatment of obesity and NASH (non-alcoholic steatohepatitis). In addition, Altimmune is developing HepTcell, an immunotherapeutic designed to achieve a functional cure for chronic hepatitis B virus (HBV).

SEC Filings

Direct access to Altimmune, Inc. (ALT) Annual Reports (10K) and Quarterly Reports (10Q) from the SEC website.

  • 2024
    • 10-Q Sep 30
    • 10-Q Jun 30
    • 10-Q Mar 31
  • 2023
    • 10-K Dec 31
    • 10-Q Sep 30
    • 10-Q Jun 30
    • 10-Q Mar 31
  • 2022
    • 10-K Dec 31
    • 10-Q Sep 30
    • 10-Q Jun 30
    • 10-Q Mar 31

Sector Comparison

How does Altimmune, Inc. compare to its competitors?

Loading chart...

Peter Lynch's Chart

This chart shows the current pricing of Altimmune, Inc. compared to its past. The addition of the earnings trend line provides further insights into the company's earnings power.

CAGR 0%
Stability 0%
loading chart...

Altimmune, Inc. Discounted Cash Flow

Fully customizable DCF calculator online for Altimmune, Inc..

0
012345678910TV
fcf$0$0$0$0$0$0$0$0$0$0$0$0
DCF$0$0$0$0$0$0$0$0$0$0$0
Value$0

Competitiveness and MOAT

High margins render the company resilient under dire circumstances, hence able to drive competitors out or acquire them. ROE and ROA measure the average flow generated by each invested dollar. Their marginal value is a forecast of future growth, and it is considered by Buffett and Munger the most important single indicator.

Years12/201412/201512/201612/201712/201812/201912/202012/202112/202212/2023TTM
Net Margins--6K%-478%-411%-362%-599%-2K%125K%-21K%-479K%
ROA--17%91%-83%-78%-38%-22%-44%-41%-42%-74%
ROE--21%996%-130%-88%-46%-22%-49%-46%-46%-78%

Safety and Stability

Being debt the number one cause of investment losses and company death, the ratio Debt/FCF is of utmost importance to guarantee safety. On the other hand the Graham’s stability measures the drawdown of earnings, hence indicating the reliability of the flow generated by the company.

Years12/201412/201512/201612/201712/201812/201912/202012/202112/202212/2023TTM
Debt over FCF--00.01-0.23-0.19-0.19-0.05-0.02-0.07--
Debt over Equity0.0400.060.120.040.040.010.010.02--
Growth Stability----85%-92%-63%-----92%

Growth

Growth can be dangerous when forecasting, simply projecting the current growth is in general wrong. A company passes through multiple phases, from being young and unprofitable, to the first periods of profitability and high growth, until it arrives at a period of regime with limited growth. Identifying in which phase the company is in may help forecasting.

Years12/201412/201512/201612/201712/201812/201912/202012/202112/202212/2023CAGR 5Y
Revenue YoY growth---232%-4%-44%41%-46%-102%-726%-43%
Earnings YoY growth--65%-6K%-126%-17%-51%134%98%-13%4%-
Equity YoY growth--9%17%102%23%-6%396%-12%-7%5%14%
FCF YoY growth--61%-6K%-110%-49%-7%261%161%-31%21%-